Details

Autor(en) / Beteiligte

• Borgogna, Cinzia
• Bruna, Riccardo
• Griffante, Gloria
• Martuscelli, Licia
• De Andrea, Marco
• Ferrante, Daniela
• Patriarca, Andrea
• Mahmoud, Abdurraouf Mokhtar
• Gaidano, Valentina
• Marchetti, Monia
• Rapezzi, Davide
• Lai, Michele
• Pistello, Mauro
• Ladetto, Marco
• Massaia, Massimo
• Gaidano, Gianluca
• Gariglio, Marisa

Titel

Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients

Ist Teil von

• Blood cancer journal (New York), 2022-01, Vol.12 (1), p.8-8, Article 8

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2022

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Understanding antibody-based SARS-CoV-2 immunity in hematologic malignancy (HM) patients following infection is crucial to inform vaccination strategies for this highly vulnerable population. This cross-sectional study documents the anti-SARS-CoV-2 humoral response and serum neutralizing activity in 189 HM patients recovering from a PCR-confirmed infection. The overall seroconversion rate was 85.7%, with the lowest values in patients with lymphoid malignancies or undergoing chemotherapy. Therapy-naive patients in the “watch and wait” status were more likely to seroconvert and display increased anti-s IgG titers. Enhanced serum neutralizing activity was observed in the following SARS-CoV-2-infected HM patient groups: (i) males; ( ii) severe COVID-19; and ( iii) “watch and wait” or “complete/partial response”. The geometric mean (GeoMean) ID50 neutralization titers in patients analyzed before or after 6 months post-infection were 299.1 and 306.3, respectively, indicating that >50% of the patients in either group had a neutralization titer sufficient to provide 50% protection from symptomatic COVID-19. Altogether, our findings suggest that therapy-naive HM patients mount a far more robust immune response to SARS-CoV-2 infection vs. patients receiving anti-cancer treatment, raising the important question as to whether HM patients should be vaccinated before therapy and/or receive vaccine formats capable of better recapitulating the natural infection.